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Abstract: Broad and potent neutralizing llama single domain antibodies (VHH) against HIV-1
targeting the CD4 binding site (CD4bs) have previously been isolated upon llama immunization.
Here we describe the epitopes of three additional VHH groups selected from phage libraries. The 2E7
group binds to a new linear epitope in the first heptad repeat of gp41 that is only exposed in the
fusion-intermediate conformation. The 1B5 group competes with co-receptor binding and the 1F10
group interacts with the crown of the gp120 V3 loop, occluded in native Env. We present biophysical
and structural details on the 2E7 interaction with gp41. In order to further increase breadth and
potency, we constructed bi-specific VHH. The combination of CD4bs VHH (J3/3E3) with 2E7 group
VHH enhanced strain-specific neutralization with potencies up to 1400-fold higher than the mixture
of the individual VHHs. Thus, these new bivalent VHH are potent new tools to develop therapeutic
approaches or microbicide intervention.
Keywords: Aids; HIV; Llama Antibodies; bi-specific VHH; pepscan; competition studies; epitope
mapping; co-crystallisation
1. Introduction
AIDS remains one of the largest global health problems and annually an estimated 1.8 million
people die an AIDS related death. While antiretroviral therapy and careful clinical management
can render HIV a chronic disease, the treatment is expensive and has many adverse effects [1].
Thus in the absence of a vaccine, prophylactic therapies to prevent HIV-1 infection are urgently
needed. The encouraging results of an antiretroviral-based gel microbicide [2] suggest that microbicidal
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prevention methods merit investigation. Recently, many broad and potent HIV neutralizing monoclonal
antibodies (mAb) have been discovered [3–11]. However, while monoclonal antibody (mAb)-based
microbicides have been evaluated before [12], the application of this is limited by their expensive
production and the need for cold distribution system. The variable domains of the heavy chain of
heavy chain only antibodies (VHH) derived from llamas or other Camelidae may be better alternatives,
as they can be produced relatively cheaply in microorganisms like bacteria or yeast [13] and are often
stable at high temperatures [14]. This is predominantly related to their small size, which is a 10-fold
smaller than that of a conventional antibody. Moreover, their small size and more than average length
of CDR 3 allows them to bind to recessed epitopes, like the CD4 binding site (CD4bs) of HIV-1.
Previous immunizations of llamas (Lama glama) have generated anti-HIV-1 VHH specific for the
CD4bs on gp120 or gp140 [15–17] with the most potent and broadest VHH, J3, neutralizing 96% of the
HIV-1 strains tested from subtypes A, B, C, D, G and circulating recombinant forms AC, ACD, AE, AG,
and BC [16]. A mix of these VHH together with J3 was tested in vitro and showed to be neutralizing as
potently as any of the individual VHH, and a 100% coverage for the panel of 60 viruses tested was
predicted. Similarly, combinations of antibodies that bind independent epitopes have also been shown
to neutralize in vitro as efficiently mixed together as when used in isolation [18].
A number of broadly neutralizing VHH, with breadths up to 82%, targeting epitopes on the HIV
envelope glycoprotein (Env) other than the CD4bs, e.g., the co-receptor binding site or gp41, have
been isolated as well, but their epitopes had not been defined [17,19,20]. Some of these VHH are able
to neutralize the few strains that are not neutralized by J3 or by 3E3, another VHH obtained from
our immunized llamas, which neutralizes 80% of virus strains [21]. By using a mix of VHH targeting
the CD4bs and VHH targeting other epitopes, broader neutralization is expected. An additional
advantage of the use of a mix of VHH is that it reduces the chance of the emergence of escape mutants.
This has been observed in studies in which a combination of some broadly neutralizing conventional
human antibodies targeting independent epitopes were passively transferred to humanized mice [3,4].
Using covalently linked VHH often has an advantage over using monovalent VHH or a mix of VHH, as
the bivalent VHH may have higher potencies than the constituent monovalent VHH, due to enhanced
avidity [22,23]. Furthermore, HIV-1 neutralization potency can be enhanced by heteroligation of two
distinct single-chain Fv (scFv), into bi-specific molecules [24]. In contrast, bi-specific VHH targeting the
CD4bs as well as the co-receptor binding site did not show any increase in potency, but an extended
breadth was confirmed. Nevertheless bi-specific VHH may have an advantage when used in gene
therapy in a vectored-immunoprophylaxis (VIP) adeno-associated virus (AAV) [25], because the size
of a bi-specific VHH genes do not exceed the maximal allowed size of the transgene insert.
Therefore, we aimed to design and produce bi-specific anti-HIV-1 VHH, which have neutralization
abilities superior to those of the two best VHH, J3 and 3E3, regarding breadth and potency, for various
applications. In order to design these molecules, i.e., to make the best combinations, we first determined
the epitopes of several VHH. VHH that bound to epitopes other than the CD4bs were linked to J3
and 3E3 and most of these bi-specific VHH have improved breadth and potency against certain viral
strains, compared to the equimolar mix of the constituent VHH.
2. Results
2.1. Competition-Based Determination of 4 Different Epitope Groups
Previously, we have selected over 100 different HIV-1 neutralizing VHH starting with various
immune libraries (Most important data summarized in Figures 1 and 2) [15–17,21,26]. To be able
to make bi-specific VHH, two VHH that target independent epitopes need to be linked together.
Preliminary evidence indicated that a number of the selected VHH do not compete with J3 or 3E3 [19].
To determine the epitopes of the preselected VHH we performed a (cross-) competition assay in
which seven of these VHH (3E3, J3, 1B5, 2E7, 1F10, 11F1F, 1H9) were tested for their competition
against each other and against six other VHH that neutralize HIV-1 (Figure 3A). In the assay, Env was
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immobilized and a total of 13 neutralizing and an irrelevant VHH were added in excess to the plate.
Following incubation, seven biotinylated VHH of interest were added and their binding was detected
via peroxidase-conjugated streptavidin (Figure 3A), showing the competition against gp140UG37
(and Table S1 showing the competition against gp120IIIB and gp140CN54). These competition assays
enabled the clear division into four groups of VHH targeting different epitopes. The first group is
comprised of phylogenetically diverse VHH (Figure 2) targeting the CD4bs, which includes J3, 3E3,
A12, D7 and C8. The second group includes phylogenetically related 2E7 and 11F1F and unrelated
VHH 11F1B and 1E2. The third group of VHH, that probably block the co-receptor binding site,
is composed of phylogenetically related 1B5, 1H9 and 2B4F and the unrelated 4D4. The fourth group
contains one VHH, 1F10, which does not fully compete with any of the other VHH, indicating that it
binds to a separate epitope. To obtain more insight into the location of the different epitopes on Env,
a competition assay was performed with these VHH versus b12 (a bnAb targeting the CD4 binding
site), 17b (a bnAb targeting the co-receptor binding site), sCD4 and anti-gp41 MPER bnAbs (2F5,
4E10) were performed (Figure 3B). This revealed that group I targets the CD4 binding site, group II
targets gp41 independent of the MPER epitope, group III targets the co-receptor binding site and group
IV also seems to target the co-receptor site (Figure 3B). Since this competition was only performed
in one way, differences in affinity between the VHH and the mAb may have led to false negatives.





Figure 1. Clade Specific Neutralization of VHH. (A) J3, (B) 3E3, (C) 2E7, (D) 1B5 and (E) 1F10. The 
total neutralization per clade is shown by the height of the bar in the graph and the neutralization 
potency by the colors of the bar. Red indicates an IC50 < 1 µg/mL, yellow between 1 and 10 µg/mL 
and green between 10 and 50 µg/mL. 
  
Figure 1. Clade Specific Neutralization of VHH. (A) J3, (B) 3E3, (C) 2E7, (D) 1B5 and (E) 1F10. The total
neutralization per clade is shown by the height of the bar in the graph and the neutralization potency
by the colors of the bar. Red indicates an IC50 < 1 µg/mL, yellow between 1 and 10 µg/mL and green
between 10 and 50 µg/mL.




Figure 2. Phylogenetic Tree and Characteristics of the Selected VHH. VHH A12 (and D7) and C8 
originate from an immunization with gp120 in llama 44, where the other VHH orginate from 
immunizations of llamas 8 and 9 with gp140 of UG037 and CN54. The neutralization (breadth), 
Medium IC50 values, epitopes (this study). 
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Figure 3. Interaction of the selected VHH with HIV-1 Env proteins. (A) Is showing the VHH 
competition among themselves for binding to gp140UG37, this is presented as a percentage. 
Gp140UG37 trimers used in this study are non-native trimers that contain a substantial amount of 
“open” Env structures. The signal observed for VHH competing with themselves was defined as 0%, 
signal during competition with an irrelevant VHH was defined as 100%. The VHH represented in the 
columns are the competing VHH, which were present in large excess. The VHH represented in the 
rows are the detected VHH. (B,C) are showing the binding of VHH (B) and bi-valent VHH (C) to 
gp140UG37, gp120IIIB and gp41, and their ability to compete with several mAbs and sCD4. Binding 
is expressed as the IC50 value in nM, competition as a percentage of the signal obtained where no 
competing VHH was present. 
  
Figure 3. Interaction of the selected VHH with HIV-1 Env proteins. (A) Is showing the VHH competition
among themselves for binding to gp140UG37, this is presented as a percentage. Gp140UG37 trimers
used in this study a e non-native trimers that contain a substantial amount of “open” Env structures.
The signal observed f r VHH competing with hemselves was defined as 0%, signal during competition
with an irrelevant VHH was defined as 100%. The VHH represented in the columns are the competing
VHH, which were present in large excess. The VHH represented in the rows are the detected VHH.
(B,C) are showing the binding of VHH (B) and bi-valent VHH (C) to gp140UG37, gp120IIIB and gp41,
and their ability to compete with several mAbs and sCD4. Binding is expressed as the IC50 value in
nM, competition as a percentage of the signal obtained where no competing VHH was present.
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2.1.1. Epitope Group I, VHH That Bind to CD4bs
This group consists of J3, 3E3, A12, C8, D7 and their family members. The VHH were obtained
directly from the phage library or selective elution with sCD4, of phages carrying these VHH. Moreover,
previous work on competition experiments of these VHH, with sCD4 and b12, pointed out that this
group of VHH is targeting the CD4bs [19]. During these studies it became clear that J3 as well as
3E3 enhance binding of 17b by approximately 3- or 4-fold, respectively. Although J3 and 3E3 are
phylogenetically not related and were selected from different llamas, they have several features in
common. For example, they share the very rare feature that they lack three residues in the CDR2
relative to their respective germ line [27]. The reinsertion of these three residues in J3 or 3E3 abrogates
the binding abilities of either VHH (data not shown and McCoy et al. [16]). Unlike e.g., VRC01, which
also binds to the CD4bs, J3 and 3E3 do not bind to RSC3, a resurfaced gp120 molecule in which there
are many alterations outside the structurally invariant part of the CD4bs, including in the bridging
sheets [9]. These data suggest that that J3 and 3E3, like CD4, bind to the bridging sheets of gp120.
Moreover, J3 in particular shows unusual degrees of maturation outside of its paratope, although less
than bnAb selected from humans. The foot print of J3 and 3E3 were determined by modeling [27].
The most characteristic feature of the binding of J3 to gp120 is that its foot print is very similar to the
foot print of CD4. It was predicted by the model that Tyr99J3 occupies a position similar to Phe43CD4
resulting in a similar hydrophobic interaction with gp120. Recently these interactions were confirmed
by co-crystallization [manuscript in preparation]. The competition assay shows that sCD4 competes
with J3, 3E3, A12 and C8 for binding to Env. However, A12 and C8 also compete with 17b, indicating
that the interaction surface of A12 is also outside the CD4bs, which is less conserved than the CD4bs
itself. This may be an explanation for the relatively low breadth of A12, which neutralized 42% of the
viruses tested.
2.1.2. Epitope Group II Consisting of 2E7, 11F1F, 1E2 and 11F1B and Their Family Members
2E7 and 11F1F share 91% DNA and 89% protein sequence identity and neutralize 21 out of 26
(81%) and 36 out of 45 (76%) viruses tested, respectively. While the potencies of 2E7 and 11F1F (median
IC50 of 19 and 21 µg/mL respectively) are much weaker than those of the CD4bs VHH 3E3 and J3, these
VHH can neutralize some viral strains (e.g., Du172.17 and CAP45.2.00.G3) that are resistant to either
3E3 or J3 (Table S1). Based on the binding and competition experiments described above it is clear
that 2E7, 11F1F, 1E2 and 11F1B bind to gp41 outside the MPER epitope as they don’t compete with
bnAbs 2F5 and 4E10. Furthermore, no competition was observed with gp41 Heptad Repeat 1 (HR1)
Abs HK20 and 3D6, that target amino acids 535–581 [8] and the immunodominant area (amino acids
579–613) [28] of gp41, respectively. Inhibition of 2E7 and 11F1F binding was seen in the presence of
antibody 246-D (epitope sequence 590-QQLLGIWG-597 with the epitope core being LLGI), suggesting
that these VHH bind to the C-terminal part of the HR1 region of gp41, but not to the epitope of 3D6,
which is 599-SGKLICTTA-607.
This region of gp41 has been characterized as being immunodominant, thus it is not surprising that
immunization of llamas with recombinant gp140 yielded antibodies targeting this region. However, it
is novel that the VHH antibodies elicited can not only neutralize HIV, but do so with a breadth ranging
across many subtypes. Therefore, the epitopes of 2E7, 11F1F, 1E2 and 11F1B were investigated by
measuring their binding to overlapping linear and cyclic 15-mer peptides covering gp160 proteins
derived from subtype A, B, C and CRF BC viruses (strains UG037, HXB2, SF162, ZM96 and CN54).
All VHH showed binding to a peptide containing the sequence AVERYLKDQQLLGIWG (corresponding
to residues 582–597 in HXB2 numbering, data not shown). Therefore, we focused on the broadest
VHH, 2E7 in the following analysis. A peptide containing the epitope of 2E7 was used as a seed for
a library in which each amino acid was uniquely substituted with Ala, Arg, Glu, Phe, Gly or Trp to
obtain a limited substitution mutagenesis scanning. Clear binding peaks were observed corresponding
to the peptides indicated in Figure 4, and were largely consistent for all tested subtypes represented
in the peptide sets. The consensus sequence for the 2E7 epitope is (I/V)ERYL(R/K)DQQL (583–592).
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The limited substitution mutagenesis screening was in good agreement with the results obtained in






Figure 4. Epitopes Determination of the VHH 2E7, 11F1F and 1F10. After initial pepscan analyses, the 
amino acids in the gp140 envelop protein that interact with these VHH have been fine mapped by 
limited substitution of the amino acids of the epitopes of 2E7 (A) and full substitution for 1F10 (B). 
The key residues of the interaction are indicated by red arrows. 
  
Figure 4. Epitopes Det rmination e VHH 2E7, 1 1F and 1F10. Af er initial pepscan analyses,
the amino aci i 0 envelop protein that interact wi these VHH hav been fine mapped by
limited substitution of the amino acids of the epitopes of 2E7 (A) and full substitution for 1F10 (B).
The key residues of the interaction are indicated by red arrows.
Gp41 residues 582 to 596 adopt a helical conformation in the native gp140 structure and form the
C-terminal part of the HR1 triple stranded coiled coil, which is hidden within the trimer interface [29].
We therefore tested binding of 2E7 to a fusion intermediate conformation of gp41 (gp41int) that
contains part of HR1 including the 2E7 epitope fused in frame to the pIIGCN4 triple stranded coiled
coil [30]. SPR measurements revealed a KD of 0.592 nM (k(on): 9.52 × 105 (1/Ms); k(off): 5.64 × 104
(1/s) (Figure 5A) corroborating the interaction of 2E7 with activated gp41 that has the HR1 coiled coil
exposed similar to the mode of action described for HR1 antibodies D5 and HK20 [31,32]. We next
solved the crystal structure of 2E7 in complex with the peptide 582-AVERYLKDQQLLGIW-596 to a
resolution of 2.9 Å (Table 1). The structure shows that the VHH interacts with the gp41 peptide in an
unusual way. The gp41 helix packs lateral to one side of the VHH beta sheet (Figure 5B). The major
contacts are hydrogen bonds between gp41 D589 and the hydroxyl and backbone amide of the CDR 2
residue T53 as well as gp41 W596 and framework residue T50. A salt bridge from gp41 K588 to CDR1
D32 (Figure 5B) and hydrophobic contacts of gp41 L592 to CDR1 A33 and CDR2 I51, and gp41 I595
and W596 to framework P47 further stabilize the interaction. Cα super-positioning of the 2E7-gp41
peptide structure and the native gp140 structure confirms that 2E7 would not be able to access the HR1
epitope which is hidden in the native Env conformation (Figure 6). We conclude that 2E7 targets the
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HR1 coiled coil, which is temporarily exposed during membrane fusion before refolding into the six
helical bundle post fusion conformation [33]. 
5 
 
Figure 5. Structural analysis of 2E7 in complex with its gp41 HR1 epitope. (A) SPR analysis of VHH 
2E7 with gp41int. 2E7 concentrations ranging from 6.25 to 100 nM were tested for binding to gp41int. 
Kinetic constants were derived by global fitting the data corresponding to the five indicated 
concentrations to a 1:1 Langmuir model (dotted lines) using local Rmax parameters. (B)Ribbon 
diagram of the crystal structure of the 2E7 VHH in complex with a gp41 HR1 peptide. The gp41 
peptide is shown in wheat and the VHH CDR regions are indicated by different colors. Polar 
interactions are shown as dashed lines. 
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of the crystal structure of the 2E7 VHH in compl x with a gp41 HR1 peptide. The gp41 peptide is
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shown as dashed lines.




Figure 6. Mapping of the VHH epitopes onto the HIV-1 BG505 trimer (PDB ID 4TVP). (A) One 
monomer of the trimer is shown as a space filling model, carbohydrates are shown as sticks. The 
positions of the different VHH epitopes determined by crystallography and/or pepscan mapping are 
show in different colors. The distances between the epitopes were estimated and used to determine 
the linker length between VHH recognizing CD4bs (J3 and 3E3 and the epitopes recognized by the 
other VHH in the construction of a set of bi-specific VHH. The gp41 residues contacted by 2E7 are 
shown in Cyan, 1F10 in green. The 2E7 epitope located on gp41 HR1 is hidden in the trimer of the 
native Env gp140 conformation and not accessible for 2E7 binding. (B) Schematic of the domain 
organization of Env and location of the epitopes. 
  
Figure 6. Mapping of the VHH epitopes onto the HIV-1 BG505 trimer (PDB ID 4TVP). (A) One monomer
of the trimer is shown as a space filling model, carbohydrates are shown as sticks. The positions
of the different VHH epitopes determined by crystallography and/or pepscan mapping are show in
different colors. The distances between the epitopes were estimated and used to determine the linker
length between VHH recognizing CD4bs (J3 and 3E3 and the epitopes recognized by the other VHH in
the construction of a set of bi-specific VHH. The gp41 residues contacted by 2E7 are shown in Cyan,
1F10 in green. The 2E7 epitope located on gp41 HR1 is hidden in the trimer of the native Env gp140
conformation and not accessible for 2E7 binding. (B) Schematic of the domain organization of Env and
location of the epitopes.
Table 1. Data collection and refinement statistics of 2E7GP41.
2E7GP41
Data Collection Native Anisotropic Scaling **
Wavelength (Å) 0.97239
Space group P22121
Cell dimensions a, b, c (Å) 37.95, 121.26, 132.21
Resolution (Å) * 44.68–2.95 (3.03–2.95) 44.68–2.95 (3.03–2.95)
Unique reflections * 13440 (993) 12538 (327)
Rmerge (%) 8.4 (76.4) 7.9 (34.2)
I/σI * 13.8 (2.3) 14.6 (3.9)
Completeness (%) * 99.0 (100.00) 96.6 (34.5)
Redundancy * 4.7 (5.0) 4.3 (1.3)
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Table 1. Cont.
2E7GP41
Data Collection Native Anisotropic Scaling **
Wilson B factor (Å2) 63.85 58.0
Refinement
Resolution 44.68–2.96 (3.07–2.96)








Bond lengths (Å) 0.006








* Values in parentheses refer to highest resolution shell; ** The data were truncated according to the Diffraction
Anisotropy Server of UCLA to 2.95 Å, 3.1 Å and 2.95 Å along a, b, c, respectively. M. Strong, M.R. Sawaya, S. Wang,
M. Phillips, D. Cascio, D. Eisenberg, Proc. Natl. Acad. Sci. USA. 103, 8060-8-65, 2006. *** Percentiles are indicated
for resolution range 2.962 Å ± 0.25 Å based on analysis with Molprobity.
2.1.3. Epitope Group III Consisting of 1B5 and 1H9 and Family Members Recognize Part of the
Co-Receptor Binding Site
Figure 3A shows that VHH 1B5 and 1H9 show a similar cross-competition pattern, moreover they
compete with each other, indicating that they target a similar epitope. They compete with 17b, but not
with b12 or sCD4 (Figure 3B). 1B5 and 1H9 were subjected to pepscan analysis, but neither bound to any
of the peptides of the arrays of overlapping linear and cyclic 15-mer peptides covering gp160 proteins
derived from various subtypes (data not shown). Escape mutant studies indicated that residues P417
and R419 [34] are involved in the interaction of 1B5 with gp120. We this suggest that group 3 VHH
target the coreceptor site largely based on the competition assays (Figure 3B). The proposed locations
of the 1B5 and 1H9 epitopes are shown in Figure 6, in which the residues P417 and R419 are shown
in magenta.
2.1.4. Epitope Group IV Consisting of 1F10 Binds to the Crown of the V3 Loop
1F10 neutralizes 18 out of the 26 viruses tested (69%). Based on the competition experiments it is
clear that 1F10 competes with 17b, but not with sCD4 or b12. It competes marginally with all the other
VHHs except for the CD4bs targeting VHH J3 and 3E3 (Figure 3 and Table S1). Furthermore, 1F10
does not compete with CD4bs antibody HJ16 either [8], supporting that this VHH binds a non-CD4bs
epitope. However, 1F10 does compete with HGN194, a neutralizing Ab which binds to the crown of
the V3 loop. Pepscan analysis with 1F10 was performed on subtype A, C and CRF BC viruses (strains
UG037, ZM96 and CN54). Clear binding peaks were observed for peptides derived from the V3 region
and were largely consistent between the three subtypes. (data not shown). The consensus sequence
for the 1F10 epitope is IRIGPGQT (307–314 according to the HXB2 numbering) which overlaps with
the HGN194 epitope RRSVRIGPGQTF (304–315). Single amino acid full replacement analyses were
performed using a cyclic peptide (CRSVRIGPGQTFYAC) and two linear peptides (KRIRIGPGQTFY
and KSINIGPGRAFA), each containing the sequence region recognized by 1F10. The replacement
analysis identified the core epitope of 1F10 as IxIGPGxT (Figure 4B). The epitope of 1F10 is depicted in
Figure 6A, where it is highlighted in green.
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2.2. Construction of Bispecific anti-HIV VHH
Of the four CD4bs (group 1) VHH, J3 and 3E3 have the broadest and most potent HIV neutralization
ability (Table S1). Thus, these two VHH were chosen for the construction of bi-specific molecules.
VHH targeting distinct epitopes were paired with either 3E3 or J3 to maximize breadth. From group 2,
VHH 2E7 and 11F1F were chosen and 1H9 is representing group 3 as it neutralizes CAP45.2.00.G3,
a strain not neutralized by J3, and because its median IC50 is lower than that of 1B5 (5 µg/mL versus
13 µg/mL). The sole representative of group 4, VHH 1F10 (targeting the V3 loop), was also chosen as
candidate for bi-specific VHH as it is broad and neutralizes at least two of the viruses (e.g., Du172.17
and CAP45.2.00.G3) J3 does not [16,17]. An overview of the neutralization IC50 values for these VHH
is given in supplementary Table S1.
VHH targeting the CD4bs were joined with VHH targeting the HR1 of gp41, the co-receptor
binding site or the V3 loop (Figure 6) by a flexible 15 or 25 amino acid glycine-serine (GGGGS)
repeat linker to form bi-specific VHH molecules. As the 15 and 25 linkers did not show a significant
difference in their functionality (data not shown), the 15 linkers were chosen for further investigation.
The bi-specific VHH with the CD4bs VHH on the N-terminal side seem to behave superior to those
with the CD4bs VHH on the C-terminal side (data not shown). The bi-specific VHH bind to all tested
Env proteins if either constituent VHH is able to bind (Figure 3C).
In general, the ability of the bi-specific VHH to compete with human bnAbs is equal to the
combined competing abilities of both monomeric components. However, for bi-specific constructs
containing 1F10, the ability to compete with 17b is reduced (J3-1F10) or turned into enhanced binding
(3E3-1F10). This may be due to conformational changes induced by J3 and 3E3, as both individual
VHH enhance 17b binding. Reduced competition with 17b is also seen with 3E3-1H9.
2.3. Broad and Potent HIV Neutralization by bi-Specific VHH Targeting a Combination of gp120 and
gp41 Epitopes
Preliminary neutralization experiments indicated that the bi-specific constructs containing 1H9
did not yield a large improvement of breadth or potency and thus it was not characterized further.
The remaining bi-specific VHH were tested for the ability to neutralize viruses resistant to either
J3 or 3E3 to test whether the breadth of the bivalent construct was higher than that of J3 and 3E3
alone. Du172.17, a subtype C tier 3 virus, is not neutralized by J3, but is neutralized by all three
J3-containing bi-specific VHH with IC50 values equal or lower than those of 1F10, 2E7 or 11F1F alone
(Figure 7A). The same holds true for TV1.2, this subtype C tier 2 virus, is resistant to 3E3, but is
neutralized by all three 3E3-containing bi-specific VHH or their mixes (Figure 7B). However, for some
combinations the mixed monomers appear to be more potent than the linked constructs, therefore
an additional six viruses from different subtypes and tiers were tested (Figure 7C). These viruses
were in some cases susceptible to neutralization by the mix of both VHH constituting the bi-specific
VHH, however, neutralization at least as potent as that of the most potent component VHH was seen
for both linked and unlinked VHH mixtures in all cases (data not shown). Dependent on the HIV
strain, some bi-specific VHH were substantially more potent than the equimolar mix of the constituent
VHH. The bi-specific VHH containing 1F10 did not show greatly enhanced potencies compared to
the equimolar mixes of the constituent VHH for any of the strains tested, whereas the bi-specific
VHH with 2E7 and 11F1F have greatly enhanced potencies up to a 1400-fold, especially on the two
C-clade viruses. For the subtype A and B viruses, approximately equivalent potency was seen for all
bi-specific VHH compared to their respective unlinked equimolar mixtures, only J3-11F1F showed an
increase in potency of a factor 6.3 against MS208.A1 and up to a 5-fold potency increase for Bal.26.
In contrast, large increases in potency for the bi-specific VHH relative to the unlinked equimolar mixes
were observed against the two subtype C viruses. A particularly large potency increase was seen for
3E3/J3-11F1F and J3-2E7 against the tier 2 ZM214M.PL15 virus and 3E3/J3-11F1F against the tier 1
96ZM651.02 virus. We conclude that the increase in breadth and potency was most efficient against
clade C with a combination of anti-CD4bs VHH and anti-gp41 VHH.
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3. Discussion
To broaden neutralization capacities, but also to reduce the chance of the emergence of escape
mutants, targeting two independent epitopes on Env is likely to be beneficial [35]. Recently, bi-specific
antibodies, targeting amongst others, the CD4bs [36,37] and MPER [38,39] showed broad and potent
neutralization. Furthermore, fusions of CD4 and mAb 17b revealed synergetic effects [36,40] as well as
VHH fusions revealed important synergistic effects [22,40,41]. To determine optimal combinations for
the construction of bi-specific VHH we first determined and characterized a number of new VHH,
which could be combined with the most potent neutralizing VHH J3 or 3E3 [16,21]. 13 new VHH were
classified into four groups recognizing non-overlapping epitopes. Only for 1F10 was some competition
seen with the epitopes of other VHH (1B5/1H9 and 2E7/11F1F). This competition is most likely due
to steric hindrance or because of conformational changes occurring after binding of one of the VHH,
preventing the binding of the other.
To determine the epitopes of the VHH binding to the three epitope groups other than the CD4bs
in more detail, we subjected the VHH of these groups to pepscan analysis. 2E7, as a representative
of epitope group 2, binds to gp41. It binds to the linear sequence (I/V)ERYL(R/K)DQQLLG(L/I)W
at position 583–596 according to the HXB2 numbering. Binding to the predicted gp41 epitope was
confirmed by the crystal structure of 2E7 in complex with a peptide of this epitope. The epitope is part
of the C-terminal part of the HR1 coiled coil that stabilizes the trimer interface in the native gp140
conformation [29,42,43]. In this native like conformation, the epitope is inaccessible to 2E7 due to
steric clashes. Instead we show that 2E7 binds with high nanomolar affinity to the fusion intermediate
conformation of gp41 that bridges the viral and cellular membranes during the initial step of membrane
fusion [33] and is occluded by HR2 in the gp41 post fusion conformation [44]. Its mode of action
is thus similar to HR1 mAbs D5, HK20 and 8066 whose epitope is located at the N-terminal part of
HR1 [31,32,45]. Although these mAbs neutralize HIV-1, their breadth and potency is largely increased
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when they are used as smaller Fabs or single chain antibodies [31,32,45], indicating that the site is
difficult to access for a conventional antibody during the fusion reaction. It therefore remains to be
tested whether 2E7 has the same breadth and potency as a complete Fc containing antibody.
1B5 and 1H9, (epitope group 3) compete with 17b, an Ab that targets the co-receptor site. This in
combination with preliminary data of co-crystallization experiments [manuscript in preparation]
suggests an epitope overlapping with the co-receptor binding site.
High resolution pepscan analysis revealed that 1F10 (epitope group 4) binds to the sequence
IRIGPGQT (HXB2 position 307–314) in the crown of the V3 loop, an epitope also targeted by the human
mAbs 447-52D and HGN194. The latter is able to prevent the mucosal transmission of a subtype C
SHIV when passively transferred [46]. The VHH described here thus target the following four distinct
epitopes: the CD4bs, cluster1/HR1 of gp41, the co-receptor binding site or the V3 loop. All of the VHH
epitopes are depicted in Figure 6A.
Bi-specific antibodies are currently investigated for a number of purposes and in general the
bi-specific antibodies are performing quite well in vitro as is demonstrated by Asokan et al. [36].
In particular the construct VRC07-PG9-16 performed very well by neutralizing up 97% of the viruses
tested with a median potency of 0.055 µg/mL. However, the situation in vivo is more complicated as
there is a reasonably high chance that the bi-specific antibody initiates an immune response. Results of
clinical trials of Ablynx show that VHH have a low risk for triggering immune responses in humans,
because of their physical-chemical properties, the folding of CDR1 and 2 and their small size.
We constructed bi-specific VHH, containing either J3 or 3E3 (epitope group 1) in combination with
a VHH that binds to an independent epitope. The constructs containing 1H9, did not show enhanced
neutralization compared to the mix of the constituent VHH in preliminary experiments, so therefore
they were not studied further. This observation agrees well with the fact that other bi-specific
VHH targeting the CD4bs and the co-receptor binding site simultaneously did not show enhanced
potency [20]. The increases in potency of the bi-specific VHH containing 1F10 were not spectacular for
the viruses that were neutralized by either constituent VHH. This suggests that 1F10 hardly binds
simultaneously with J3 or 3E3. The bi-specific VHH with the CD4bs VHH on the N-terminal side
neutralize superior to those with the CD4bs VHH on the C-terminal side. The largest improvements in
potencies, up to 1400-fold, are obtained with the constructs containing the gp41 targeting 2E7 or 11F1F
as counterparts. The improvements are highest towards the viruses 96ZM651.02 and ZM214, both
C-clade viruses, whereas towards the viruses from other clades, the improvements are less than 10-fold.
Unexpectedly, J3-11F1F as well as 3E3-11F1F showed more than 200-fold increased potencies towards
ZM214, whereas monomeric 11F1F was unable to neutralize this virus at a concentration of less than
1 µM. A plausible explanation for this may be that the binding of J3 or 3E3 causes conformational
changes that allow 11F1F to bind or enhance 11F1F binding, confirming an epitope present on the
intermediate conformation of HR1.
4. Methods
4.1. Materials and Methods
4.1.1. Proteins
Monoclonal antibodies b12 (EVA3065, by Dr D. P. Burton [47], 17b (ARP3071 by Dr J. Robinson) [48],
2F5 (EVA 3063, by Dr H. Katinger), 4E10 (ARP3239, by Polymun), and L120 ARP359, by Becton
Dickinson) the recombinant proteins gp120IIIB (EVA607, by ImmunoDiagnostics), gp140UG37 (ARP698,
by Polymun), gp140CN54 (ARP699 by Polymun), gp41 (ARP680) and human soluble CD4 (EVA609,
by ImmunoDiagnostics) were obtained through the Centralized Facility for AIDS Reagents (CFAR),
the National Institute for Biological Standards and Controls (NIBSC).
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4.1.2. Viruses
Replication competent virus stocks were prepared from HIV-1 molecular clones by transfection
of 293T cells. HIV-1 envelope pseudotyped viruses were produced in 293T cells by co-transfection
with the pSG3∆env plasmid. The subtype B and C HIV-1 Reference Panels of Env Clones [49,50]
were obtained through the NIH AIDS Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH, USA. The 96ZM651.02 gp160 clone was kindly provided by Dr D. Montefiori (Duke
University Medical Center, Durham, NC) through the Comprehensive Antibody Vaccine Immune
Monitoring Consortium (CA2 VIMC) as part of the Collaboration for AIDS Vaccine Discovery (CAVD).
All additional pseudoviruses were produced at the VIMC laboratory.
4.1.3. Cells
TZM-bl cells [49,51,52] were obtained through the NIH AIDS Research and Reference Reagent
Program from J. C. Kappes, X. Wu, and Tranzyme, Inc., and cultured in Dulbecco’s modified Eagle
medium (Invitrogen) containing 10% (v/v) fetal calf serum (FCS).
4.1.4. VHH
A12, C8 and D7 were described by [15], and the 3D structure of D7 (highly homologous to A12)
has been determined by Hinz et al. [53] A12 has been analyzed with EM tomography in complex with
trimeric spikes [54]. 2E7, 1F10 and 1B5 are described in reference [17]. Selection of 1H9, 2B4F, 11F1F,
11F1B were not described earlier in detail (manuscript in preparation), J3 and 3E3 have previously
been described [16,17,21]. VHH were purified as described previously [16,17].
4.2. Cross-Competition Assay
To be able to detect only one of the two VHH that are present during this assay, part of them had
to be biotinylated. NHS-LC-LC-biotin (Thermo scientific, Cat. No: 21343), was incubated 10:1 with
VHH, 1 h, RT. Unbound biotin was removed by dialysis. Biotinylated VHH (bVHH) were titrated.
MaxiSorp plates were coated with 100 ng/well gp140UG37 or gp140CN54 (for J3 250 ng gp140CN54)
or 250 ng for gp120IIIB 250. After blocking, competing (non-biotinylated) VHH was added for 1 h.
As control, binding of all competing VHH was detected separately. Subsequently 10 µL b-VHH
was added to the competing VHH in concentration determined previously. B-VHH was detected
by horseradish peroxidase (HRP) conjugated Streptavidin and visualized by o-Phenylenediamine,
supplemented with 0.03% H2O2. Reaction was stopped using 1 M H2SO4 and signals measured
at 490 nm. These values were then converted to percentages, in which competition with itself was
regarded as maximal competition, i.e., 0%, and the competition against an irrelevant VHH as the
unhindered binding, i.e., 100%.
4.3. Binding to Various Env Proteins
MaxiSorp plates were coated o/n with 100 ng gp140UG37, gp120IIIB or gp41. After blocking VHH
(mono or bivalent) were added and detected by mouse anti Myc (9E10) and peroxidase conjugated
donkey anti mouse (DAMPO). Visualization occurred as stated above.
4.4. Competition Assay with mAbs and sCD4
MaxiSorp plates were coated o/n with 100 ng gp140UG37 (for b12, 17b, sCD4 and partially 2F5
competition) or gp41 (4E10 and partially 2F5 competition). After blocking, VHH (mono or bivalent)
were added and allowed to bind for 1 h, RT. 10 µL of competitor was added to the wells in a final
concentration of 0.4 µg/mL b12, 1 µg/mL 17b, 0.07 µg/mL 4E10, 0.07 µg/mL 2F5 (gp140UG37) or
0.6 µg/mL 2F5 (gp41). Competitors mAbs b12, 17b, 2F5 and 4E10 were detected with peroxidase
conjugated goat anti human (Jackson Immunoresearch), sCD4 by L120 and peroxidase conjugated
donkey anti mouse. Visualization occurred as stated above.
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For the titrated competition assays, MaxiSorp plates were coated overnight at 4 ◦C with 200 ng
per well gp140UG37 (for 3E3, 1H9 and 1F10 competition) or gp41 (2E7 and 11F1F competition).
Following blocking, the binding of HRP conjugated streptavidin to biotinylated VHH was detected
using TMB-ELISA substrate (Pierce).
4.5. Construction of bi-Specific VHH
Essentially the procedure described by Hultberg 2011 has been followed, in short N- and
C-terminal VHH fragments were amplified from their expression vectors, by PCR using DreamTaq
green (Fermentas). Primers were used that annealed just outside of the VHH coding region and
would add a linker and restriction sites to allow cloning of the N and C terminal VHH respectively.
The resulting PCR products were purified using the NucleoSpin® Extract II kit (Machery-Nagel,
Düren, Germany), restricted with the appropriate enzymes and cloned into the VHH expression vector.
Bacteria were transformed with the constructs by heatshock and subsequently clones were picked
for sequence analysis. Bi-specific VHH were expressed in bacteria and purified by metal affinity
chromatography in the same way as the monovalent VHH, which has been described before [16,17].
4.6. HIV Neutralization Assay
The HIV-1 neutralizing activities of the VHH were assessed in the TZM-bl cell based assay,
as described previously [15–17]. No virus inactivation was observed with a negative control VHH.
Cells were lysed with Bright-Glo luciferase reagent (Promega, Madison, WI, USA) and the luminescence
measured. Fifty % inhibitory concentration (IC50) titers were calculated using the XLFit4 software
(ID Business Solutions, Guildford, UK).
4.7. Epitope Mapping
The binding of VHH to arrays of peptides was assessed in a pepscan-based ELISA. Each well
in the card contained covalently linked peptides that were incubated overnight at 4 ◦C with VHH,
at a concentration of approximately 1 µg/mL, in PBS supplemented with 1% BSA and 0.1% Tween
80. After washing, the plates were incubated with a mouse anti-Histidine followed by HRP linked
Rabbit anti-mouse (Southern Biotech, Birmingham, AL, USA) for 1 h at 25 ◦C. After further washing,
peroxidase activity was assessed with an ABTS based substrate. The color development was quantified
after 60 min using a charge-coupled device camera and an image-processing system.
4.8. Crystal Structure of VHH 2E7 in Complex with a gp41 Peptide
Purified VHH 2E7 was incubated with a 1.5 M excess of the gp41 peptide 582-AVERYLKD
QQLLGIW-596 and crystallized at a concentration of 2.5 mg/mL. Crystals were obtained by the vapor
diffusion method in sitting drops, with equal volumes of protein and reservoir solution (in 0.1M Hepes
pH 7.0, 30% PEG 6000). The crystal was cryo-cooled at 100 K in absence of surrounding liquid [55].
A complete dataset was collected at the ESRF (Grenoble, France) beamline ID29. Data were processed
and scaled with MOSFLM [56], and SCALA [57]. The crystals belong to space group P212121 with
unit cell dimensions of a = 37.95 Å, b = 121.26 Å, c = 132.21 Å and three copies of the 2E7-gp41
peptide complex. The structure was solved by molecular replacement using PHASER [58] and the
VHH structure from Protein Data Bank (PDB) ID 3EZJ as a search model. An initial model was built
with ARP/wARP [59] and completed by several cycles of manual model building with Coot [60] and
refinement with Refmac [61] using data to 2.9 Å resolution. The final model contains 2E7 residues
1–120 and gp41 residues 582 to 596. The R and Rfree of the refined model are 19.5 and 24.6, respectively
with 99% of the residues in the allowed regions of a Ramachandran plot. Molecular graphics figures
were generated with PyMOL (W. Delano; http://www.pymol.org). Coordinates and structure factures
have been deposited in the Protein Data Bank with accessions code 5HM1 (2E7).
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4.9. SPR Analysis of 2E7 Binding to gp41int
The fusion intermediate conformation of gp41, gp41int was purified as described before [30].
Surface plasmon resonance (SPR) analysis was performed with a Biacore 3000 (GE Healthcare). As a
flow buffer 10 mM HEPES, 150 mM NaCl, pH 7.4 with 0.005% Tween-20 was used. Gp41int was
immobilized to ~1200 response units using 50 µg/mL protein in flow buffer on an activated CM-5
sensor chip (GE Healthcare: BR-1000-50) according to the manufacturer’s instructions. Specific binding
to the target protein was corrected for nonspecific binding to the deactivated control channel. The flow
rate was 50 µL/min. Regeneration of the sensor chip was achieved with 10mM HCl followed by 4 M
MgCl2 for 60 s at 60 µL/min. Data were analyzed with the BIA evaluation software version 4.1 and
globally fit to t a 1:1 Langmuir model double referenced by subtraction of the blank surface and a
blank injection.
5. Conclusions
Using various techniques we selected VHH against 4 different epitopes on HIV 1 gp140.
This enabled us to rationally design bi-specific VHH. We show that increased potencies and extended
breadths can be achieved by bi-specific VHH targeting two independent epitopes most likely on the
same trimer, thereby producing important synergistic effects. Due to the lower risk of development of
escape mutants and an improved efficacy, bi-specific anti-HIV-1 VHH may have great advantages over
monovalent VHH in preventing HIV-1 transmission, either in a topical microbicide or when expressed
from a gene therapy vector. Moreover, the lower production costs and higher stability of bi-specific
VHH, make them superior to conventional antibodies. Because of its breadth and potency, VHH J3
was tested against SHIVs in a macaque challenge study quite successfully (manuscript in preparation).
At present the mono- and bispecific VHH are tested on their capability to recognize and destroy
immune cells infected by HIV-1. Furthermore, an AAV based vector expressing VHH may provide
prevention against infection and additional effects might be achieved by adding human Fc fragments
to bi-specific VHH to suppress viremia, as was shown recently for the human antibody 3BNC117 [62].
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4468/8/2/38/s1,
Table S1: Summary of neutralization data.
Author Contributions: N.M.S. Experimental setup and execution, data analysis, drafting of manuscript; M.H.
Experimental setup and execution, data analysis; L.R. Experimental setup, data analysis, drafting of manuscript;
L.E.M. Experimental setup and execution, data analysis, drafting of manuscript; J.W.B. Experimental setup and
execution, data analysis; C.C. Experimental setup and execution, data analysis; M.H. Experimental setup and
execution, data analysis; R.A.W. Study design and intellectual input, critical revising of the manuscript; W.W.
data analysis, drafting of manuscript, critical revising of the manuscript; T.V. Study design and intellectual input,
critical revising of the manuscript.
Funding: This research received no external funding.
Acknowledgments: This research received funding of the European Commission sixth Frame Work Programme
as part of the European Vaccines and Microbicides Enterprise (EUROPRISE), the European Commission seventh
Frame Work Programme as part of the Combined Highly Active Anti-retroviral Microbicides project (CHAARM),
the Bill and Melinda Gates Foundation as part of the Collaboration for AIDS Vaccine Discovery (CAVD grant
38637 (to R.A. Weiss), grant 38619 (to M.S. Seaman)), the UK Medical Research Council (to R. Weiss), the Institute
Universitaire de France (IUF) (to W. Weissenhorn) and a post doctoral fellowship from Sidaction (to M. Hock and
W. Weissenhorn). Further, Winfried Weissenhorn acknowledges the platforms of the Grenoble INSTRUCT-ERIC
center (ISBG; UMS 3518 CNRS-CEA-UJF-EMBL) supported by the French Infrastructure for Integrated Structural
Biology Initiative FRISBI (ANR-10-INSB-05-02) and GRAL (ANR-10-LABX-49-01) within the Grenoble Partnership
for Structural Biology (PSB), the ESRF-EMBL Joint Structural Biology Group for access and support at the
ESRF beam lines and J. Marquez (EMBL) from the crystallization platform. The authors would like to thank
Mohamed ElKhattabi for llama immunizations, Dennis Burton for the kind gift of b12 and Davide Corti and
Antonio Lanzavecchia for the kind gifts of HJ16, HGN194 and HGP120 and Mike Seamen for the determination of
neutralization breadth for individual VHH.
Conflicts of Interest: The authors declare that there are no competing financial interest, other than that N.M.S.,
L.R., L.E.M., R.A.W. and T.V. are inventors on a patent that is filed on the use of several VHH mentioned in
this paper. In the period we carried out this research 4 persons were related to companies, Nika M Strokappe,
Lucy Rutten and myself worked at UU or later at QVQ Holding b.v. and Jaap W. Back at Pepscan. All others
Antibodies 2019, 8, 38 16 of 19
worked either in the teams of Robin Weiss or Winfried Weissenhorn. Later on Jaap went to Eurofins, Miriam to
Immunocore and Matthias to Novartis. However none of these companies were involved in this work. For all
clarity, QVQ become member of the Gates project from 2011 onwards. Most of the work described in this paper
was done in the period 2011–2015.
References
1. Granelli-Piperno, A.; Pritsker, A.; Pack, M.; Shimeliovich, I.; Arrighi, J.F.; Park, C.G.; Trumpfheller, C.;
Piguet, V.; Moran, T.M.; Steinman, R.M. Dendritic cell-specific intercellular adhesion molecule 3-grabbing
nonintegrin/CD209 is abundant on macrophages in the normal human lymph node and is not required for
dendritic cell stimulation of the mixed leukocyte reaction. J. Immunol. 2005, 175, 4265–4273. [CrossRef]
[PubMed]
2. Abdool Karim, Q.; Abdool Karim, S.S.; Frohlich, J.A.; Grobler, A.C.; Baxter, C.; Mansoor, L.E.; Kharsany, A.B.;
Sibeko, S.; Mlisana, K.P.; Omar, Z.; et al. CAPRISA 004 Trial Group Effectiveness and safety of tenofovir gel,
an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, 329, 1168–1174.
[CrossRef] [PubMed]
3. Klein, F.; Gaebler, C.; Mouquet, H.; Sather, D.N.; Lehmann, C.; Scheid, J.F.; Kraft, Z.; Liu, Y.; Pietzsch, J.;
Hurley, A.; et al. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a
new conformational epitope on the HIV-1 envelope protein. J. Exp. Med. 2012, 209, 1469–1479. [CrossRef]
[PubMed]
4. Klein, F.; Halper-Stromberg, A.; Horwitz, J.A.; Gruell, H.; Scheid, J.F.; Bournazos, S.; Mouquet, H.; Spatz, L.A.;
Diskin, R.; Abadir, A.; et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized
mice. Nature 2012, 492, 118–122. [CrossRef] [PubMed]
5. Scheid, J.F.; Mouquet, H.; Feldhahn, N.; Seaman, M.S.; Velinzon, K.; Pietzsch, J.; Ott, R.G.; Anthony, R.M.;
Zebroski, H.; Hurley, A.; et al. Broad diversity of neutralizing antibodies isolated from memory B cells in
HIV-infected individuals. Nature 2009, 458, 636–640. [CrossRef] [PubMed]
6. Walker, L.M.; Phogat, S.K.; Chan-Hui, P.Y.; Wagner, D.; Phung, P.; Goss, J.L.; Wrin, T.; Simek, M.D.; Fling, S.;
Mitcham, J.L.; et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1
vaccine target. Science 2009, 326, 285–289. [CrossRef] [PubMed]
7. Scheid, J.F.; Mouquet, H.; Ueberheide, B.; Diskin, R.; Klein, F.; Oliveira, T.Y.; Pietzsch, J.; Fenyo, D.; Abadir, A.;
Velinzon, K.; et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4
binding. Science 2011, 333, 1633–1637. [CrossRef] [PubMed]
8. Corti, D.; Langedijk, J.P.; Hinz, A.; Seaman, M.S.; Vanzetta, F.; Fernandez-Rodriguez, B.M.; Silacci, C.;
Pinna, D.; Jarrossay, D.; Balla-Jhagjhoorsingh, S.; et al. Analysis of memory B cell responses and isolation of
novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS ONE 2010,
5, e8805. [CrossRef] [PubMed]
9. Wu, X.; Yang, Z.Y.; Li, Y.; Hogerkorp, C.M.; Schief, W.R.; Seaman, M.S.; Zhou, T.; Schmidt, S.D.; Wu, L.; Xu, L.;
et al. Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1.
Science 2010, 329, 856–861. [CrossRef] [PubMed]
10. Walker, L.M.; Huber, M.; Doores, K.J.; Falkowska, E.; Pejchal, R.; Julien, J.P.; Wang, S.K.; Ramos, A.;
Chan-Hui, P.Y.; Moyle, M.; et al. Broad neutralization coverage of HIV by multiple highly potent antibodies.
Nature 2011, 477, 466–470. [CrossRef] [PubMed]
11. Huang, J.; Ofek, G.; Laub, L.; Louder, M.K.; Doria-Rose, N.A.; Longo, N.S.; Imamichi, H.; Bailer, R.T.;
Chakrabarti, B.; Sharma, S.K.; et al. Broad and potent neutralization of HIV-1 by a gp41-specific human
antibody. Nature 2012, 491, 406–412. [CrossRef] [PubMed]
12. Brinckmann, S.; da Costa, K.; van Gils, M.J.; Hallengard, D.; Klein, K.; Madeira, L.; Mainetti, L.; Palma, P.;
Raue, K.; Reinhart, D.; et al. Rational design of HIV vaccines and microbicides: Report of the EUROPRISE
network annual conference 2010. J. Transl. Med. 2011, 9, 40. [CrossRef] [PubMed]
13. van de Laar, T.; Visser, C.; Holster, M.; Lopez, C.G.; Kreuning, D.; Sierkstra, L.; Lindner, N.; Verrips, T.
Increased heterologous protein production by Saccharomyces cerevisiae growing on ethanol as sole carbon
source. Biotechnol. Bioeng. 2007, 96, 483–494. [CrossRef] [PubMed]
14. Gorlani, A.; Brouwers, J.; McConville, C.; van der Bijl, P.; Malcolm, K.; Augustijns, P.; Quigley, A.F.; Weiss, R.;
De Haard, H.; Verrips, T. Llama antibody fragments have good potential for application as HIV type 1 topical
microbicides. AIDS Res. Hum. Retroviruses 2012, 28, 198–205. [CrossRef] [PubMed]
Antibodies 2019, 8, 38 17 of 19
15. Forsman, A.; Beirnaert, E.; Aasa-Chapman, M.M.; Hoorelbeke, B.; Hijazi, K.; Koh, W.; Tack, V.; Szynol, A.;
Kelly, C.; McKnight, A.; et al. Llama antibody fragments with cross-subtype human immunodeficiency virus
type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120. J. Virol. 2008, 82, 12069–12081.
[CrossRef] [PubMed]
16. McCoy, L.E.; Quigley, A.F.; Strokappe, N.M.; Bulmer-Thomas, B.; Seaman, M.S.; Mortier, D.; Rutten, L.;
Chander, N.; Edwards, C.J.; Ketteler, R.; et al. Potent and broad neutralization of HIV-1 by a llama antibody
elicited by immunization. J. Exp. Med. 2012, 209, 1091–1103. [CrossRef] [PubMed]
17. Strokappe, N.; Szynol, A.; Aasa-Chapman, M.; Gorlani, A.; Forsman Quigley, A.; Hulsik, D.L.; Chen, L.;
Weiss, R.; de Haard, H.; Verrips, T. Llama antibody fragments recognizing various epitopes of the CD4bs
neutralize a broad range of HIV-1 subtypes A, B and C. PLoS ONE 2012, 7, e33298. [CrossRef] [PubMed]
18. Doria-Rose, N.A.; Louder, M.K.; Yang, Z.; O’Dell, S.; Nason, M.; Schmidt, S.D.; McKee, K.; Seaman, M.S.;
Bailer, R.T.; Mascola, J.R. HIV-1 neutralization coverage is improved by combining monoclonal antibodies
that target independent epitopes. J. Virol. 2012, 86, 3393–3397. [CrossRef] [PubMed]
19. Strokappe, N.M. HIV-1, How Llamas Help Us Fight the AIDS Pandemic; Utrecht University: Utrecht,
The Netherlands, 2013.
20. Matz, J.; Kessler, P.; Bouchet, J.; Combes, O.; Ramos, O.H.; Barin, F.; Baty, D.; Martin, L.; Benichou, S.; Chames, P.
Straightforward selection of broadly neutralizing single-domain antibodies targeting the conserved CD4 and
coreceptor binding sites of HIV-1 gp120. J. Virol. 2013, 87, 1137–1149. [CrossRef] [PubMed]
21. McCoy, L.E.; Rutten, L.; Frampton, D.; Anderson, I.; Granger, L.; Bashford-Rogers, R.; Dekkers, G.;
Strokappe, N.M.; Seaman, M.S.; Koh, W.; et al. Molecular Evolution of Broadly Neutralizing Llama
Antibodies to the CD4-Binding Site of HIV-1. PLoS Pathog. 2014, 10, e1004552. [CrossRef] [PubMed]
22. Hultberg, A.; Temperton, N.J.; Rosseels, V.; Koenders, M.; Gonzalez-Pajuelo, M.; Schepens, B.; Itati Ibanez, L.;
Vanlandschoot, P.; Schillemans, J.; Saunders, M.; et al. Llama-derived single domain antibodies to build
multivalent, superpotent and broadened neutralizing anti-viral molecules. PLoS ONE 2011, 6, e17665.
[CrossRef] [PubMed]
23. Jahnichen, S.; Blanchetot, C.; Maussang, D.; Gonzalez-Pajuelo, M.; Chow, K.Y.; Bosch, L.; De Vrieze, S.;
Serruys, B.; Ulrichts, H.; Vandevelde, W.; et al. CXCR4 nanobodies (VHH-based single variable domains)
potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc. Natl. Acad. Sci. USA 2010,
107, 20565–20570. [CrossRef] [PubMed]
24. Mouquet, H.; Warncke, M.; Scheid, J.F.; Seaman, M.S.; Nussenzweig, M.C. Enhanced HIV-1 neutralization by
antibody heteroligation. Proc. Natl. Acad. Sci. USA 2012, 109, 875–880. [CrossRef] [PubMed]
25. Balazs, A.B.; West, A.P., Jr. Antibody gene transfer for HIV immunoprophylaxis. Nat. Immunol. 2013, 14, 1–5.
[CrossRef] [PubMed]
26. Forsman Quigley, A.; Strokappe, N.; McCoy, L.; Rutten, L.; Tan, S.; Aasa-Chapman, M.; Seaman, M.; Szynol, A.;
Liu, Y.Y.; de Haard, H.; et al. Broadly neutralising single-chain llama antibody fragments targeting novel
gp120 and gp41 epitopes on the human immunodeficiency virus type 1 (HIV-1) envelope spike. manuscript
in preparation.
27. McCoy, L.; Rutten, L.; Strokappe, N.; Verrips, T.; Webb, B.; Weiss, R. Broadly neutralizing VHH againstHIV-1.
WO Patent WO2013036130A1, 14 March 2013.
28. Xu, J.Y.; Gorny, M.K.; Palker, T.; Karwowska, S.; Zolla-Pazner, S. Epitope mapping of two immunodominant
domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human
monoclonal antibodies. J. Virol. 1991, 65, 4832–4838. [PubMed]
29. Pancera, M.; Zhou, T.; Druz, A.; Georgiev, I.S.; Soto, C.; Gorman, J.; Huang, J.; Acharya, P.; Chuang, G.Y.;
Ofek, G.; et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 2014, 514, 455–461.
[CrossRef] [PubMed]
30. Lai, R.P.; Hock, M.; Radzimanowski, J.; Tonks, P.; Hulsik, D.L.; Effantin, G.; Seilly, D.J.; Dreja, H.; Kliche, A.;
Wagner, R.; et al. A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1. J. Biol. Chem.
2014, 289, 29912–29926. [CrossRef]
31. Luftig, M.A.; Mattu, M.; Di Giovine, P.; Geleziunas, R.; Hrin, R.; Barbato, G.; Bianchi, E.; Miller, M.D.;
Pessi, A.; Carfi, A. Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody.
Nat. Struct. Mol. Biol. 2006, 13, 740–747. [CrossRef]
Antibodies 2019, 8, 38 18 of 19
32. Sabin, C.; Corti, D.; Buzon, V.; Seaman, M.S.; Lutje Hulsik, D.; Hinz, A.; Vanzetta, F.; Agatic, G.; Silacci, C.;
Mainetti, L.; et al. Crystal structure and size-dependent neutralization properties of HK20, a human
monoclonal antibody binding to the highly conserved heptad repeat 1 of gp41. PLoS Pathog. 2010, 6, e1001195.
[CrossRef]
33. Weissenhorn, W.; Hinz, A.; Gaudin, Y. Virus membrane fusion. FEBS Lett. 2007, 581, 2150–2155. [CrossRef]
[PubMed]
34. Grupping, K. Inhibiting the CD4-gp120 Interaction to Prevent HIV Infection: Insights from Mutational
Resistance Analysis. Ph.D. Thesis, Universiteit Antwerpen, Antwerp, Belgium, 2013.
35. Pennings, P.S. Standing Genetic Variation and the Evolution of Drug Resistance in HIV. PLoS Comput. Biol.
2012, 8, e1002527. [CrossRef] [PubMed]
36. Asokan, M.; Rudicell, R.S.; Louder, M.; McKee, K.; O’Dell, S.; Stewart-Jones, G.; Wang, K.; Xu, L.; Chen, X.;
Choe, M.; et al. Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and
Potent Neutralization. J. Virol. 2015, 89, 12501–12512. [CrossRef] [PubMed]
37. Liu, L.; Patel, B.; Ghanem, M.H.; Bundoc, V.; Zheng, Z.; Morgan, R.A.; Rosenberg, S.A.; Dey, B.; Berger, E.A.
Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and
Absence of HIV Entry Receptor Activity. J. Virol. 2015, 89, 6685–6694. [CrossRef] [PubMed]
38. Bournazos, S.; Gazumyan, A.; Seaman, M.S.; Nussenzweig, M.C.; Ravetch, J.V. Bispecific Anti-HIV-1
Antibodies with Enhanced Breadth and Potency. Cell 2016, 165, 1609–1620. [CrossRef] [PubMed]
39. Huang, Y.; Yu, J.; Lanzi, A.; Yao, X.; Andrews, C.D.; Tsai, L.; Gajjar, M.R.; Sun, M.; Seaman, M.S.; Padte, N.N.;
et al. Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity. Cell 2016, 165, 1621–1631.
[CrossRef] [PubMed]
40. Dey, B.; Del Castillo, C.S.; Berger, E.A. Neutralization of human immunodeficiency virus type 1 by sCD4-17b,
a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor. J. Virol.
2003, 77, 2859–2865. [CrossRef] [PubMed]
41. Lutje Hulsik, D.; Liu, Y.Y.; Strokappe, N.M.; Battella, S.; El Khattabi, M.; McCoy, L.E.; Sabin, C.; Hinz, A.;
Hock, M.; Macheboeuf, P.; et al. A gp41 MPER-specific llama VHH requires a hydrophobic CDR3 for
neutralization but not for antigen recognition. PLoS Pathog. 2013, 9, e1003202. [CrossRef] [PubMed]
42. Julien, J.P.; Cupo, A.; Sok, D.; Stanfield, R.L.; Lyumkis, D.; Deller, M.C.; Klasse, P.J.; Burton, D.R.; Sanders, R.W.;
Moore, J.P.; et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013, 342, 1477–1483.
[CrossRef]
43. Lyumkis, D.; Julien, J.P.; de Val, N.; Cupo, A.; Potter, C.S.; Klasse, P.J.; Burton, D.R.; Sanders, R.W.; Moore, J.P.;
Carragher, B.; et al. Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science
2013, 342, 1484–1490. [CrossRef] [PubMed]
44. Weissenhorn, W.; Dessen, A.; Harrison, S.C.; Skehel, J.J.; Wiley, D.C. Atomic structure of the ectodomain
from HIV-1 gp41. Nature 1997, 387, 426–430. [CrossRef] [PubMed]
45. Gustchina, E.; Li, M.; Louis, J.M.; Anderson, D.E.; Lloyd, J.; Frisch, C.; Bewley, C.A.; Gustchina, A.;
Wlodawer, A.; Clore, G.M. Structural basis of HIV-1 neutralization by affinity matured Fabs directed against
the internal trimeric coiled-coil of gp41. PLoS Pathog. 2010, 6, e1001182. [CrossRef] [PubMed]
46. Sholukh, A.M.; Watkins, J.D.; Vyas, H.K.; Gupta, S.; Lakhashe, S.K.; Thorat, S.; Zhou, M.; Hemashettar, G.;
Bachler, B.C.; Forthal, D.N.; et al. Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and
systemic IgG1 mAbs: Complete protection of rhesus monkeys from mucosal SHIV challenge. Vaccine 2015,
33, 2086–2095. [CrossRef] [PubMed]
47. Burton, D.R.; Barbas, C.F., 3rd; Persson, M.A.; Koenig, S.; Chanock, R.M.; Lerner, R.A. A large array of
human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of
asymptomatic seropositive individuals. Proc. Natl. Acad. Sci. USA 1991, 88, 10134–10137. [CrossRef]
[PubMed]
48. Thali, M.; Moore, J.P.; Furman, C.; Charles, M.; Ho, D.D.; Robinson, J.; Sodroski, J. Characterization of
conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4
binding. J. Virol. 1993, 67, 3978–3988. [PubMed]
49. Li, M.; Gao, F.; Mascola, J.R.; Stamatatos, L.; Polonis, V.R.; Koutsoukos, M.; Voss, G.; Goepfert, P.; Gilbert, P.;
Greene, K.M.; et al. Human immunodeficiency virus type 1 env clones from acute and early subtype
B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 2005,
79, 10108–10125. [CrossRef] [PubMed]
Antibodies 2019, 8, 38 19 of 19
50. Li, M.; Salazar-Gonzalez, J.F.; Derdeyn, C.A.; Morris, L.; Williamson, C.; Robinson, J.E.; Decker, J.M.;
Li, Y.; Salazar, M.G.; Polonis, V.R.; et al. Genetic and neutralization properties of subtype C human
immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections
in Southern Africa. J. Virol. 2006, 80, 11776–11790. [CrossRef] [PubMed]
51. Derdeyn, C.A.; Decker, J.M.; Sfakianos, J.N.; Wu, X.; O’Brien, W.A.; Ratner, L.; Kappes, J.C.; Shaw, G.M.;
Hunter, E. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by
coreceptor specificity defined by the V3 loop of gp120. J. Virol. 2000, 74, 8358–8367. [CrossRef] [PubMed]
52. Wei, X.; Decker, J.M.; Liu, H.; Zhang, Z.; Arani, R.B.; Kilby, J.M.; Saag, M.S.; Wu, X.; Shaw, G.M.; Kappes, J.C.
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20)
monotherapy. Antimicrob. Agents Chemother. 2002, 46, 1896–1905. [CrossRef] [PubMed]
53. Hinz, A.; Lutje Hulsik, D.; Forsman, A.; Koh, W.W.; Belrhali, H.; Gorlani, A.; de Haard, H.; Weiss, R.A.;
Verrips, T.; Weissenhorn, W. Crystal Structure of the Neutralizing Llama V(HH) D7 and Its Mode of HIV-1
gp120 Interaction. PLoS ONE 2010, 5, e10482. [CrossRef] [PubMed]
54. Meyerson, J.R.; Tran, E.E.; Kuybeda, O.; Chen, W.; Dimitrov, D.S.; Gorlani, A.; Verrips, T.; Lifson, J.D.;
Subramaniam, S. Molecular structures of trimeric HIV-1 Env in complex with small antibody derivatives.
Proc. Natl. Acad. Sci. USA 2013, 110, 513–518. [CrossRef] [PubMed]
55. Pellegrini, E.; Piano, D.; Bowler, M.W. Direct cryocooling of naked crystals: Are cryoprotection agents always
necessary? Acta Crystallogr. D Biol. Crystallogr. 2011, 67, 902–906. [CrossRef] [PubMed]
56. Battye, T.G.; Kontogiannis, L.; Johnson, O.; Powell, H.R.; Leslie, A.G. iMOSFLM: A new graphical interface
for diffraction-image processing with MOSFLM. Acta Crystallogr. D Biol. Crystallogr. 2011, 67, 271–281.
[CrossRef] [PubMed]
57. Evans, P. Scaling and assessment of data quality. Acta Crystallogr. D Biol. Crystallogr. 2006, 62, 72–82.
[CrossRef] [PubMed]
58. McCoy, A.J. Solving structures of protein complexes by molecular replacement with Phaser. Acta Crystallogr.
D Biol. Crystallogr. 2007, 63, 32–41. [CrossRef] [PubMed]
59. Perrakis, A.; Morris, R.; Lamzin, V.S. Automated protein model building combined with iterative structure
refinement. Nat. Struct. Biol. 1999, 6, 458–463. [CrossRef] [PubMed]
60. Emsley, P.; Cowtan, K. Coot: Model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr.
2004, 60, 2126–2132. [CrossRef]
61. Murshudov, G.N.; Vagin, A.A.; Dodson, E.J. Refinement of macromolecular structures by the maximum-
likelihood method. Acta Crystallogr. D Biol. Crystallogr. 1997, 53, 240–255. [CrossRef]
62. Caskey, M.; Klein, F.; Lorenzi, J.C.; Seaman, M.S.; West, A.P., Jr.; Buckley, N.; Kremer, G.; Nogueira, L.;
Braunschweig, M.; Scheid, J.F.; et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing
antibody 3BNC117. Nature 2015, 522, 487–491. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
